IP Library › Granted Patent US 12,569,592
Granted Patent B2
US 12,569,592 · App. 17/532,893 · Granted Mar 10, 2026

Genetically modified pigs for xenotransplantation of vascularized xenografts and derivatives thereof

Inventor: David Ayares (Blacksburg, VA)
Assignee: Revivicor, Inc.
A61L27/3604A01K67/0271A01K67/0275A01K67/0278A61K45/06C12N15/8509A01K2217/052A01K2217/075A01K2227/108A01K2267/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,569,592
App. No.
17/532,893
Granted
Mar 10, 2026
Kind
B2
Abstract

The present invention provides certain donor animals, tissues and cells that are particularly useful for xenotransplantation therapies. In particular, the invention includes porcine animals, as well as tissue and cells derived from these, which lack any expression of functional alpha 1,3 galactosyltransferase (aGT) and express one or more additional transgenes which make these animals suitable donors for xenotransplantation of vascularized xenografts and derivatives thereof. Methods of treatment and using organs, tissues and cells derived from such animals are also provided.

Claims (49)

1 . A transgenic animal comprising genetic modifications that result in:

(i) lack of any expression of a functional alpha 1,3 galactosyltransferase (GTKO); and

(ii) incorporation into the genome and expression of:

a cytoprotective transgene that is ubiquitously expressed or is under the control of a constitutive promoter, wherein the cytoprotective transgene is selected from the group consisting of HO-1, FAT-1, A20, and soluble tumor necrosis factor-alpha (TNF-alpha) receptor; and

an immunosuppressant transgene selected from the group consisting of cluster of differentiation 47 (CD47), and Class II transactivator-DN (CIITA-DN);

one anticoagulant transgene under the control of an endothelial cell-specific promoter, wherein the at least one anticoagulant transgene is endothelial protein C receptor (EPCR) or thrombomodulin (TBM);

wherein the EPCR or the TBM is expressed in an aorta, a lung, a kidney, a heart, a liver, an intestine, a stomach, or a spleen; and

wherein the transgenic animal is a transgenic ungulate.

2 . The transgenic animal of claim 1 , wherein:

(i) at least two transgenes are under the control of an endothelial cell-specific promoter;

or

(ii) the endothelial cell-specific promoter is ICAM-2 or Tie-2.

3 . The transgenic animal of claim 2 , further comprising one additional transgene, wherein the one additional transgene is a complement inhibitor transgene, and wherein the complement inhibitor transgene is selected from the group consisting of CD46, DAF (CD55), CD59, and CR1.

4 . The transgenic animal of claim 3 , wherein:

(i) the anticoagulant transgene is thrombomodulin;

(ii) the cytoprotective transgene is HO-1;

(iii) the immunosuppressant transgene is CD47; and

(iv) the complement inhibitor transgene is CD46 or CD55.

5 . The transgenic animal of claim 3 , wherein the anticoagulant transgene is EPCR, and

(i) the complement inhibitor transgene is CD46 or CD59;

(ii) the cytoprotective transgene is HO-1; and

(iii) the immunosuppressant transgene is CD47.

6 . The transgenic animal of claim 1 , wherein the transgenic animal expresses two anticoagulant transgenes, and wherein the two anticoagulant transgenes are TBM and EPCR.

7 . A cell isolated from the transgenic animal of claim 1 .

8 . An organ isolated from the transgenic animal of claim 1 .

9 . The organ of claim 8 , wherein the organ is selected from the group consisting of heart, lung, liver, and kidney.

10 . A tissue isolated from the transgenic animal of claim 1 .

11 . The tissue of claim 10 , wherein the tissue is selected from the group consisting of vascular tissue, retinal tissue, and corneal tissue.

12 . The tissue of claim 11 , wherein the vascular tissue is a vascular graft.

13 . A method for xenotransplantation comprising administering to a primate in need thereof organs, tissues, or cells isolated from the transgenic animal of claim 1 .

14 . The method of claim 13 , wherein the primate is a human.

15 . The method of claim 13 , wherein:

(i) the organ is selected from the group consisting of heart, lung, liver, and kidney; or

(ii) the tissue is selected from the group consisting of vascular tissue, retinal tissue and corneal tissue.

16 . The transgenic animal of claim 1 , wherein the transgenic animal comprises a nucleic acid sequence of SEQ ID NO: 7, SEQ ID NO: 10, or a complementary sequence thereof.

17 . A transgenic porcine animal comprising genetic modifications that result in:

(i) lack of expression of functional alpha 1,3 galactosyltransferase; and

(ii) incorporation into the genome and expression of

(a) two complement inhibitor transgenes, wherein the two complement inhibitors are CD46 and DAF; CD46 and CD59; or DAF and CD59, and wherein the complement inhibitors are ubiquitously expressed and are under the control of a constitutive promoter; and

(b) two anticoagulant transgenes under the control of an endothelial cell-specific promoter, wherein the two anticoagulant transgenes are endothelial protein C receptor (EPCR), and thrombomodulin, and wherein the EPCR and the thrombomodulin are expressed in an aorta, a lung, a kidney, a heart, a liver, an intestine, a stomach, or a spleen; and

(c) a CD47 transgene under the control of a constitutive promoter.

18 . A transgenic porcine animal comprising genetic modifications that result in:

(i) lack of expression of functional alpha 1,3 galactosyltransferase; and

(ii) incorporation into the genome and expression of:

(a) one complement inhibitor transgene, wherein the complement inhibitor is selected from the group consisting of CD46 and DAF, and wherein the complement inhibitor is ubiquitously expressed and is under the control of a constitutive promoter;

(b) a CD47 transgene under the control of a constitutive promoter;

(c) a HO-1 transgene; and

(d) one anticoagulant transgene under the control of an endothelial cell-specific promoter, wherein the anticoagulant transgene is selected from the group consisting of endothelial protein C receptor (EPCR) and thrombomodulin, and

wherein the anticoagulant transgene is expressed in an aorta, a lung, a kidney, a heart, a liver, an intestine, a stomach, or a spleen.

Continuity (4)
Continuation 13966121 · Aug 13, 2013
Continuation PCTUS2012025097 · Feb 14, 2012
Provisional Application 61442504 · Feb 14, 2011
Related Publication 20220072200A1 · Mar 10, 2022
References Cited (184)
US 4736866A · Leder et al. · 1988 [cited by applicant]
US 4873191A · Wagner et al. · 1989 [cited by applicant]
US 4888274A · Radding et al. · 1989 [cited by applicant]
US 4944384A · Herron · 1990 [cited by applicant]
US 5057420A · Massey · 1991 [cited by applicant]
US 5334575A · Noonan et al. · 1994 [cited by applicant]
US 5453457A · Meltzer et al. · 1995 [cited by applicant]
US 5496720A · Susko-Parrish et al. · 1996 [cited by applicant]
US 5523226A · Wheeler · 1996 [cited by applicant]
US 5730403A · Johnson · 1998 [cited by applicant]
US 5747340A · Harats et al. · 1998 [cited by applicant]
US 5821117A · Sandrin et al. · 1998 [cited by applicant]
US 5859307A · Mombaerts et al. · 1999 [cited by applicant]
US 5945577A · Stice et al. · 1999 [cited by applicant]
US 5977318A · Linsley et al. · 1999 [cited by applicant]
US 6066725A · DeBoer et al. · 2000 [cited by applicant]
US 6147276A · Campbell et al. · 2000 [cited by applicant]
US 6153428A · Gustafsson et al. · 2000 [cited by applicant]
US 6166288A · Diamond et al. · 2000 [cited by applicant]
US 6215041B1 · Stice et al. · 2001 [cited by applicant]
US 6235969B1 · Stice et al. · 2001 [cited by applicant]
US 6252133B1 · Campbell et al. · 2001 [cited by applicant]
US 6258998B1 · Damiani et al. · 2001 [cited by applicant]
US 6376743B1 · Yanagimachi · 2002 [cited by applicant]
US 6413769B1 · Gustafsson et al. · 2002 [cited by applicant]
US 6423316B1 · Riesbeck et al. · 2002 [cited by applicant]
US 6506559B1 · Fire et al. · 2003 [cited by applicant]
US 6525243B1 · Stockman Campbell et al. · 2003 [cited by applicant]
US 6548741B2 · Desousa et al. · 2003 [cited by applicant]
US 6573099B2 · Graham · 2003 [cited by applicant]
US 6639122B1 · Tu et al. · 2003 [cited by applicant]
US 6872868B1 · Wagner et al. · 2005 [cited by applicant]
US 7304033B2 · Larsen et al. · 2007 [cited by applicant]
US 7368284B2 · Koike · 2008 [cited by applicant]
US 7378569B2 · Tu et al. · 2008 [cited by applicant]
US 7462466B2 · Morgan et al. · 2008 [cited by applicant]
US 7755462B2 · Fullerton et al. · 2010 [cited by applicant]
US 20010044937A1 · Schatten et al. · 2001 [cited by applicant]
US 20020062492A1 · Lubon et al. · 2002 [cited by applicant]
US 20020068713A1 · Rade et al. · 2002 [cited by applicant]
US 20020108132A1 · Rapp · 2002 [cited by applicant]
US 20030014770A1 · Gustafsson et al. · 2003 [cited by applicant]
US 20050155095A1 · Koike · 2005 [cited by applicant]
US 20050223418A1 · Koike · 2005 [cited by applicant]
US 20060068479A1 · Koike · 2006 [cited by applicant]
US 20070113297A1 · Yang et al. · 2007 [cited by applicant]
US 20070286845A1 · Harats et al. · 2007 [cited by applicant]
US 20090186097A1 · Ayares · 2009 [cited by applicant]
US 20130347134A1 · Diacovo et al. · 2013 [cited by applicant]
US 20140017215A1 · Ayares · 2014 [cited by applicant]
US 20150106962A1 · Sachs et al. · 2015 [cited by applicant]
US 20180249688A1 · Ayares et al. · 2018 [cited by applicant]
US 20210392863A1 · Kim et al. · 2021 [cited by applicant]
CN 1582332 · 2005 [cited by applicant]
CN 108949832A · 2018 [cited by applicant]
WO WO9003432 · 1990 [cited by applicant]
WO WO9421799 · 1994 [cited by applicant]
WO WO9424274 · 1994 [cited by applicant]
WO WO9426884 · 1994 [cited by applicant]
WO WO9520661 · 1995 [cited by applicant]
WO WO9528412 · 1995 [cited by applicant]
WO WO9707668 · 1997 [cited by applicant]
WO WO9707669 · 1997 [cited by applicant]
WO WO9807841 · 1998 [cited by applicant]
WO WO9815626A2 · 1998 [cited by applicant]
WO WO9830683 · 1998 [cited by applicant]
WO WO9907829 · 1999 [cited by applicant]
WO WO9949029 · 1999 [cited by applicant]
WO WO9953042 · 1999 [cited by applicant]
WO WO9957266 · 1999 [cited by applicant]
WO WO0004217 · 2000 [cited by applicant]
WO WO0022098 · 2000 [cited by applicant]
WO WO0031126 · 2000 [cited by applicant]
WO WO0051424 · 2000 [cited by applicant]
WO WO0130966 · 2001 [cited by applicant]
WO WO03005810 · 2003 [cited by applicant]
WO WO03055302 · 2003 [cited by applicant]
WO WO03059923 · 2003 [cited by applicant]
WO WO2004016742 · 2004 [cited by applicant]
WO WO2004028243 · 2004 [cited by applicant]
WO WO2007035213 · 2007 [cited by applicant]
WO WO2009069986 · 2009 [cited by applicant]
WO WO2011020120 · 2011 [cited by applicant]
WO WO2012112586A1 · 2012 [cited by applicant]
WO WO2014066505 · 2014 [cited by applicant]
WO WO2016065046 · 2016 [cited by applicant]
WO WO2017044864A1 · 2017 [cited by applicant]
WO WO2019185936A2 · 2019 [cited by applicant]
WO WO2020085788A1 · 2020 [cited by applicant]
D'Apice et al. Xenotransplantation: The Next Generation of Engineered Animals. Transplant Immunology, 2009. 21:111-115. [cited by examiner]
Fisicaro et al. Efficient Co-Expression of Multiple Graft-Protective Transgenes Using The 2A System. Xenotransplantation 2007; 14(4):383. [cited by examiner]
Cooper et al., “Clinical lung xenotransplantation—what donor genetic modifications may be necessary?”, Xenotransplantation, 2012, 19:144-158. [cited by applicant]
Li et al., “Rosa26-targeted swine models for stable gene over-expression and Cre-mediated lineage tracing,” Cell Research, 2014, 24:501-504. [cited by applicant]
Mohiuddin et al., “Chimeric 2C1OR4 anti-CD40 antibody therapy is critical for long-term survival of GTKO.ACD46.hTBM pig-to-primate cardiac xenograft,” Nature Communications, vol. 7:11138, Apr. 5, 2016, pp. 1-10. [cited by applicant]
Lee et al., “Recombinase mediated cassette exchange at AAVS1 site in porcine fibroblast cell line,” Proceedings of the Korean Veterinary Medical Association, Oct. 2015, 544, abstract P300. [cited by applicant]
Aigner et al., “Transgenic pigs for xenotransplantation: Selection of promoter sequences for reliable transgene expression,” Current Opinion in Organ Transplantation, 2010, 15:201-206. [cited by applicant]
Ayares, “Genetic Modification of Pigs for Regenerative Medicine”, Presentation from UC Davis Transgenic Animal Research Conference VII, Aug. 20, 2009. [cited by applicant]
Ayares, David. “Genetic Modification of Pigs for Xenotransplantation,” Transgenic Research, vol. 19, No. 143 (2010) (pp. 12-31). [cited by applicant]
Bach et al., “Delayed xenograft rejection”, Immunol Today, 1996, vol. 17(8), pp. 379-384. [cited by applicant]
Bronson et al., “Single-copy transgenic mice with chosen-site integration,” Proc. Natl. Acad. Sci. USA, Aug. 1996, 93:9067-9072. [cited by applicant]
Byrne et al., “Increased Immunosuppression, Not Anticoagulation, Extends Cardiac Xenograft Survival,” Transplantation, 2006, 82:1787-1791. [cited by applicant]
Byrne et al., “Transgenes Expressing Human CD59 and Decay-Accelerative Factor Produce an Intrinsic Barrier to Complement-Mediated Damage1,” Transplantation, 1997, 63(1):149-155. [cited by applicant]
Chen et al., “Complete Inhibition-of Acute Humoral Rejection Using Regulated Expression of Membrane-tethered Anticoagulants on Xenograft Endothelium”, American Journal of Transplantation, 2004, vol. 4, pp. 1958-1963. [cited by applicant]
Chen et al., “Inhibition of intravascular thrombosis in murine endotoxemia by targeted expression of hirudin and tissue factor pathway inhibitor analogs to activated endothelium”, Blood, 2004, vol. 104(5), pp. 1344-1349. [cited by applicant]
Costa et al., “Expression of the human al ,2-fucosyltransferase in transgenic pigs modifies the cell surf ace carbohydrate phenotype and confers resistance to human serum-mediated cytolysis”, FASEB J, 1999, vol. 13, pp.… [cited by applicant]
Cowan et al., “Coagulation and the xenograft endothelium”, Xenotransplantation, 2007, vol. 14(1), pp. 7-12. [cited by applicant]
Cozzi et al., “Preliminary study in a life supporting pig to primate xenotransplantation model using GAL KO pigs transgenic for human CD39, CD55, CD59 and fucosyltransferase,” (Abstract LB IXA O-4), Xenotransplantation,… [cited by applicant]
Dai et al., “Targeted disruption of the a1 ,3-galactosyltransferase gene in cloned pigs”, Nature Biotechnology, 2002, vol. 20, pp. 251-255. [cited by applicant]
Dalmasso et al., “Reaction of Complement With Endothelial Cells in a Model of Xenotransplantation”, Clin. Exp. Immunol., 1991, vol. 86, pp. 31-35. [cited by applicant]
Dalmasso et al., “Inhibition of Complement-Mediated Endothelial Cell Cytotoxicity By Decay-Accelerating Factor”, Transplantation, 1991, vol. 52(3), pp. 530-533. [cited by applicant]
Denning et al., “Deletion of the a(1,3)galactosyl transferase (GGTA 1) gene and the prion protein (PrP) gene in sheep”, Nature Biotechnology, 2001, vol. 19, pp. 559-562. [cited by applicant]
Diamond et al., “Human CD59 expressed in transgenic mouse hearts inhibits the activation of complement”, Transplant Immunology, 1995, vol. 3, pp. 305-312. [cited by applicant]
Dwyer et al., “Thromboregulatory manifestations in human CD39 transgenic mice and the implications for thrombotic disease and transplantation”, The Journal of Clinical Investigation, 2004, vol. 113(10), pp. 1440-1446. [cited by applicant]
Galili et al., “Man, Apes, and Old World Monkeys Differ from Other Mammals in the Expression of a-Galactosyl Epitopes on Nucleated Cells”, The Journal of Biological Chemistry, 1988, vol. 263, pp. 17755-17762. [cited by applicant]
Genbank Accession No. NM_213888.1, 2 pages, downloaded from http://www.ncbi.nlm.nih.gov/nuccore/NM_213888.1 on Feb. 9, 2015. [cited by applicant]
Giraldo et al,. “Size matters: use of YACs, BACs and PACs in transgenic animals,” Transgenic Research, 2001, 10:83-103. [cited by applicant]
Gock et al., “Genetic modification of pigs for solid organ xenotransplantation,” Transplantation Reviews, Jan. 2011, 25:9-20. [cited by applicant]
Godwin et al., “Towards endothelial cell-specific transgene expression in pigs: characterization of the pig ICAM-2 promoter”, Xenotransplantation, 2006, vol. 13(6), pp. 514-521. [cited by applicant]
Harrison et al., “Efficient generation of a.(1,3) galactosyltransferase knockout porcine fetal fibroblasts for nuclear transfer”, Transgenic Research, 2002, vol. 11, pp. 143-150. [cited by applicant]
Houdebine, Louis-Marie, “Relations between animal transgenesis and reproduction,” Reprod. Nutr. Dev., 2005, 45:363-376. [cited by applicant]
Koike et al., “Direct gene replacement of the mouse a(l,3)-galactosyltransferase gene with human a(l,2)-fucosyltransferase gene: Converting a-galactosyl epitopes into H anti.gens”, Xenotransplantation, 1997, vol. 4, pp.… [cited by applicant]
Lai et al., “.Production of a-1,3-Galactosyltransferase Knockout Pigs by Nuclear Transfer Cloning”, Science, 2002, vol. 295, pp. 1089-1092. [cited by applicant]
Larin et al., “A method for linking yeast artificial chromosomes,” Nucleic Acids Research, 1996, 24(21):4192-4196. [cited by applicant]
Lee et al., “Characterization of Transgenic Pigs That Express Human Decay Accelerating Factor and Cell Membrane-tethered Human Tissue Factor Pathway Inhibitor”, Reprod Dom Anim, 2010, pp. 1-8. [cited by applicant]
Lui et al., “Mammary gland-specific secretion of biologically active immunosuppressive agent cytotoxic-T lymphocyte antigen 4 human immunoglobulin fusion protein (CTLA4lg) in milk by transgenesis”, Journal of Immunologi… [cited by applicant]
Martin et al., “Transgenic expression of CTLA4-Ig by fetal pig neurons for xenotransplantation”, Transgenic Research, 2005, vol. 14, pp. 373-384. [cited by applicant]
Mirenda et al., “Achieving Permanent Survival of Islet Xenografts by Independent Manipulation of Direct and Indirect T-Cell Responses”, Diabetes, 2005, vol. 54, pp. 1048-1055. [cited by applicant]
Miyagawa et al., “Remodeling of the Major Pig Xenoantigen by N-Acetylglucosaminyltransferase III in Transgenic Pig”, The Journal of Biological Chemistry, 2001, vol. 276(42), pp. 39310-39319. [cited by applicant]
Mohiuddin et al., “One-Year Heterotopic Cardiac Xenograph Survival in a Pig to Baboon Model,” Am. J. Transplant, Feb. 2014, 14(2):488-489. [cited by applicant]
Neimann et al. “Production and characterization of multi-transgenic pigs for xenotransplantation,” Transgenic Research, vol. 19 (2010) (pp. 143-144). [cited by applicant]
Niemann et al., “Production and Characterization of Multi-transgenic Pigs for Xeno Transplantation,” Transgenic Research, 2010, 19:143-144. [cited by applicant]
Phelps et al., “Production of u 1,3-Galactosyltransferase Deficient Pigs”, Science, 2003, vol. 299, pp. 411-414. [cited by applicant]
Piedrahita et al., “Cloning and transgenesis in mammals: Implications for xenotransplantation,” American Journal of Transplantation, 2004, 4(Suppl.6):43-50. [cited by applicant]
Ramsoondar et al., “Production of al, 3-Galactosyltransferase-Knockout Cloned Pigs Expressing Human al, 2-Fucosylosyltransferase”, Biology of Reproduction, 2003, vol. 69, pp. 437-445. [cited by applicant]
Sachs et al., “Genetic Manipulation in Pigs,” Curr. Opin. Organ Transplant., Apr. 2009, 14(2):148-153. [cited by applicant]
Schlaeger et al., “Uniform vascular-endothelial-cell-specific gene expression in both embryonic and adult transgenic mice”, 1997, vol. 94(7), pp. 3058-3063. [cited by applicant]
Shimizu et al., “Thrombotic Microangiopathic Glomerulopathy in Human Decay Accelerating Factor-Transgenic Swine-to-Baboon Kidney Xenografts,” J. Am. Soc. Nephrol., 2005, 16:2732-2745. [cited by applicant]
Sprangers et al., “Xenotransplantation: Where are we in 2008?”, Kidney International, Apr. 16, 2008, 74:14-21. [cited by applicant]
Squinto, “Xenogeneic organ transplantation”, Current Opinion in Biotechnology, Dec. 1996, vol. 7(6), pp. 641-645. [cited by applicant]
Stone et al., “Porcine and Bovine Cartilage Transplants in Cynomolgus Monkey”, Transplantation, 1997, vol. 63(5), pp. 640-645. [cited by applicant]
Strahan et al., “Pig alphal,3Galactosyltransferase: a Major Target for Genetic Manipulation in Xenotransplantation”, Frontiers in Bioscience, 1996, vol. 1, pp. 34-41. [cited by applicant]
Sutherland et al., “Protective Effect Of CTLA4lg Secreted By Transgenic Fetal Pancreas Allografts”, Transplantation, 2000, vol. 69(9), pp. 1806-1812. [cited by applicant]
Tai et al., “Progress in Xenotransplantation Following the Introduction of Gene-knockout Technology,” Transplant International, 2007, 20:107-117. [cited by applicant]
Tanemura et al., “Reduction of the Major Swine Xenoantigen, the a-Galactosyl Epitope by Transfection of the a2,3-Sialyltransferase Gene”, The Journal of Biological Chemistry, 1998, vol. 273(26), pp. 16421-16425. [cited by applicant]
Van de Wouwer et al., “Thrombomodulin-Protein C-EPCR System : Integrated to Regulate Coagulation and Inflammation”, Arterioscler Thromb Vasc Biol, 2004, vol. 24, pp. 1374-1383. [cited by applicant]
Van der Windt et al., “Rapid loss of intraportally transplanted islets: an overview of pathophysiology and preventive strategies”, Xenotransplantation, Jul. 2007, vol. 14(4), pp. 288-297. [cited by applicant]
Vaughan et al., “Porcine CTLA4-lg Lacks a MYPPPY Motif, Binds Inefficiently to Human B7 and Specifically Suppresses Human CD4 T Cell Responses Costimulated by Pig But Not Human B7”, The Journal of Immunology, 2000, pp. … [cited by applicant]
Ye et al., “Evidence That Intravenously Administered a-Galactosyl Carbohydrates Reduce Baboon Serum Cytotoxicity To Pig Kidney Cells (PK15) and Transplanted Pig Hearts”, Transplantation, 1994, vol. 58, pp. 330-337. [cited by applicant]
Quadros et al., “Insertion of sequences at the original provirus integration site of mouse ROSA26 locus using the CRISPR/Cas9 system”, FEBS Open Bio, 2015, 5:191-197. [cited by applicant]
Beaton et al., “GGTA-1 targeting efficiency with a xenograft transgene”, 2012, retrieved from https://mospace.umsystem.edu/xmlui/handle/10355/35385# on Aug. 31, 2022. [cited by applicant]
Kim et al., “Knock-in Somatic Cells of Human Decay Accelerating Factor and a1,2-Fucosyltransferase Gene on the a1,3-Galactosyltransferase Gene Locus of Miniature Pig”, Reprod Dev Biol, 2015, 39(3):59-67. [cited by applicant]
Kim et al., “Porcine Knock-in Fibroblasts Expressing hDAF on a-1,3-Galactosyltransferase (GGTA1) Gene Locus”, Asian-Aust. J. Anim. Sci., 2012, 25:1473-1480. [cited by applicant]
Olsson et al., “The pancreatic islet endothelial cell: Emerging roles in islet function and disease,” The International Journal of Biochemistry & Cell Biology, 2006, 38:492-497. [cited by applicant]
U.S. Appl. No. 17/531,416, filed Nov. 19, 2021. [cited by applicant]
Ayares, David et al.: “Genetic Engineering of Source Pigs for Xenotransplantation: Progress and Prospects”, Xenotransplantation, Sep.-Oct. 2013, vol. 20, No. 5, 408, Sep. 20, 2013 (Sep. 20, 2013), p. 361. [cited by applicant]
Burdorf et al., “Day Xeno Lung Recipient Survival—Progress towards the Clinic,” Journal of Heart and Lung Transplantation, Apr. 2019, 38(4):S39, 72. [cited by applicant]
Cooper et al., “Recent Advances in Understanding Xenotransplantation: Implications for the Clinic”, Expert Review of Clinical Immunology, Sep. 1, 2015, 11(12):1379-1390. [cited by applicant]
Deng et al., “Use of a 2A Peptide for Generation of Multi-Transgenic Pigs through a Single Round of Nuclear Transfer,” PLos One, May 13, 2011, 6(5):1-9, e19986. [cited by applicant]
Estrada et al., “Evaluation of Human and Non-Human Primate Antibody Binding to Pig Cells Lacking GGTA1/CMAH/b4GalNT2 genes,” Xenotransplantation, Mar. 1, 2015, 22:194-202. [cited by applicant]
Fisicaro et al., “Versatile Co-Expression of Graft-Protective Proteins Using 2A-Linked Cassettes: Transgene Co-Expression Using 2A,” Xenotransplantation, Mar. 1, 2011, 18(2):121-130. [cited by applicant]
Gock et al., “Genetic Modification of Pigs for Solid Organ Xenotransplantation,” Transplantation Reviews, Jan. 2011, 25(1):9-20. [cited by applicant]
Hai et al. “One-step generation of knockout pigs by zygote injection of CRISPR/Cas system,” Cell Research, vol. 24 (2014) (pp. 372-375). [cited by applicant]
Harris et al., “Lung Xenotransplantation: Recent Progress and Current Status, ” Xenotransplantation, 2014, 21(6):496-506. [cited by applicant]
Harris et al., “Meta-Analysis of 1-8, the Independent and Cumulative Effects of 11-27 Multiple Genetic Modifications on Pig Lung Xenograft Performance During Ex Vivo Perfusion with Human Blood,” Xenotransplantation, Dec… [cited by applicant]
Iwase et al., “Immunological and Physiological Observations in Baboons with Life-Supporting Genetically Engineered Pig Kidney Grafts,” Xenotransplantation, Mar. 17, 2017, 24(2):e12293, 1-31. [cited by applicant]
Iwase et al., “Pig Kidney Graft Survival in a Baboon for 136 Days: Longest Life-Supporting Organ Graft Survival to Date,” Xenotransplantation, Jun. 29, 2015, 22(4):302-309. [cited by applicant]
Kemter et al., “Xeno-organ donor pigs with multiple genetic modifications—the more the better?”, Current Opinion in Genetics & Development, Jun. 30, 2020, 64:60-65. [cited by applicant]
Kriz et al., “A plasmid-based multigene expression system for mammalian cells,” Nat. Commun., 2010, 1:120, 1-6 and Supplemental material 1-21. [cited by applicant]
Niu et al., “Porcine genome engineering for xenotransplantation,” Advanced Drug Delivery Reviews, 2021, 168:229-245. [cited by applicant]
Nottle et al. “Production of homozygous a-1,3-galactosyh:ransferase knockout pigs by breeding and somatic cell nuclear transfer,” Xenotransplantation, vol. 14, No. 4 (2007) (pp. 339-344). [cited by applicant]
Pierson et al., “Progress Toward Cardiac Xenotransplantation,” Circulation, 142(14):1389-1398. [cited by applicant]
Salvaris et al., “IXA-0-7.1: Multi-Gene Constructs to Accelerate the Generation of Multi-Transgenic Ga1T Knockout Pigs,” Xenotransplantation, Sep. 2009, 16(5):373. [cited by applicant]
Tena et al., “Transgenic Expression of Human CD47 Markedly Increases Engraftment in a Murine Model of Pig-to-Human Hematopoietic Cell Transplantation,” Am. J. Transplant., 2014, 14(12):2713-2722. [cited by applicant]
Ulrichts et al., “Shielding of the A1 Doman by the D D3 Domains of von Willebrand Factor Modulates its Interaction with Platelet Glycoprotein lb-IX-V *;” The Journal of Biological Chemistry, Feb. 24, 2006; 281(8):4699-4… [cited by applicant]
Wei, Deng et al.: “Use of the 2A Peptide for Generation of Multi-Transgenic Pigs through a Single Round of Nuclear Transfer”, Plos One, vol. 6, No. 5, May 13, 2011 (May 13, 2011), p. e19986. [cited by applicant]
Yu et al., “Lentiviral Vectors with two Independent Internal Promoters Transfer High-Level Expression of Multiple Transgenes to Human Hematopoietic Stem-Progenitor Cells,” Mol. Ther., 2003, 7(6):827-838. [cited by applicant]
Cooper et al., “Experimental Pig Heart Xenotransplantation—Recent Progress and Remaining Problems,” Ann. Thorac. Surg., Apr. 2019, 107(4):989-992. [cited by applicant]
Definition of “permit”, Dictionary.com, 2024, 1-6. [cited by applicant]
Hinrichs et al., “Inactivation of the GHR gene—a strategy to overcome excess growth of orthotopic pig-to-baboon cardiac xenografts?”, Xenotransplantation, 2017, 24(e12328):39-40, Abstract O.6.2, Abstracts of the 14th Co… [cited by applicant]
Ohtsuka et al., “One-step generation of multiple transgenic mouse lines using an improved Pronuclear Injection-based Targeted Transgenesis (i-PITT),” MBC Genomics, 2015, 16:274, 1-16. [cited by applicant]
Phelps et al., “Production and characterization of transgenic pigs expressing porcine CTLA4-lg,” Xenotransplantation, Nov.-Dec. 2009, 16(6):477-485. [cited by applicant]
Fischer et al., “Multi-transgenic pigs for xenotransplantation,” Xenotransplantation, 2013, 20:64; Berlin Symposium on Xenotransplantation 2012—Abstracts. [cited by applicant]
Hinrichs et al., “Growth hormone receptor knockout in GTKO/hCD46/hTM pigs as a strategy to prevent overgrowth of orthotopic xeno-hearts in baboons,” Xenotransplantation, 2019, 26(5):Abstract 225.3. [cited by applicant]
Hurh et al., “Expression Analysis of Combinatorial Genes Using a Bi-Cistronic T2A Expression System in Porcine Fibroblasts,” PLoS One, Jul. 2013, 8(7): e70486, 1-11. [cited by applicant]